215 related articles for article (PubMed ID: 34518311)
21. Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
Gadwa J; Amann M; Bickett TE; Knitz MW; Darragh LB; Piper M; Van Court B; Bukkapatnam S; Pham TT; Wang XJ; Saviola AJ; Deak LC; Umaña P; Klein C; D'Alessandro A; Karam SD
Cell Rep Med; 2023 Aug; 4(8):101150. PubMed ID: 37586327
[TBL] [Abstract][Full Text] [Related]
22. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
Tam K; Schoppy DW; Shin JH; Tay JK; Moreno-Nieves U; Mundy DC; Sunwoo JB
Otolaryngol Head Neck Surg; 2018 Jul; 159(1):76-84. PubMed ID: 29436278
[TBL] [Abstract][Full Text] [Related]
23. CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model.
Yun J; Saddawi-Konefka R; Goldenson B; Al-Msari R; Bernareggi D; Thangaraj JL; Tang S; Patel SH; Luna SM; Gutkind JS; Kaufman D
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702144
[TBL] [Abstract][Full Text] [Related]
24. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
25. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV
Lu S; Concha-Benavente F; Shayan G; Srivastava RM; Gibson SP; Wang L; Gooding WE; Ferris RL
Oral Oncol; 2018 Mar; 78():186-193. PubMed ID: 29496049
[TBL] [Abstract][Full Text] [Related]
26. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
Jung EK; Chu TH; Vo MC; Nguyen HPQ; Lee DH; Lee JK; Lim SC; Jung SH; Yoon TM; Yoon MS; Cho D; Lee JJ; Cho HH
Cytotherapy; 2022 Sep; 24(9):905-915. PubMed ID: 35778350
[TBL] [Abstract][Full Text] [Related]
27. Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice.
Toliver-Kinsky TE; Lin CY; Herndon DN; Sherwood ER
Infect Immun; 2003 Jun; 71(6):3058-67. PubMed ID: 12761083
[TBL] [Abstract][Full Text] [Related]
28. Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment.
Matsumura N; Mandai M; Hamanishi J; Yamaguchi K; Fukuhara K; Yagi H; Higuchi T; Takakura K; Fujii S
Oncol Rep; 2008 Feb; 19(2):505-15. PubMed ID: 18202801
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy.
Wang H; Dai J; Hou S; Qian W; Li B; Ma J; Fan X; Zhao J; Yang S; Sang H; Yang Q; Wang R; Guo Y
Cancer Gene Ther; 2005 Sep; 12(9):769-77. PubMed ID: 15877081
[TBL] [Abstract][Full Text] [Related]
30. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
[TBL] [Abstract][Full Text] [Related]
31. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
33. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
34.
Mac Donald A; Guipouy D; Lemieux W; Harvey M; Bordeleau LJ; Guay D; Roméro H; Li Y; Dion R; Béland K; Haddad E
Front Immunol; 2023; 14():1231916. PubMed ID: 37675109
[TBL] [Abstract][Full Text] [Related]
35. Exploring NK-Cell molecules that impact the immune response and microenvironment in head and neck squamous cell carcinoma.
Shao P; Hu WW; Shi XL; Shu MY; Li DY; Zhou T; Zhao QT
J Cell Mol Med; 2024 Jan; 28(2):e18045. PubMed ID: 38011007
[TBL] [Abstract][Full Text] [Related]
36. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
37. Head and neck cancer triggers the internalization of TLR3 in natural killer cells.
Xie L; Pries R; Kesselring R; Wulff S; Wollenberg B
Int J Mol Med; 2007 Oct; 20(4):493-9. PubMed ID: 17786279
[TBL] [Abstract][Full Text] [Related]
38. CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
Labiano S; Roh V; Godfroid C; Hiou-Feige A; Romero J; Sum E; Rapp M; Boivin G; Wyss T; Simon C; Bourhis J; Umaña P; Trumpfheller C; Tolstonog GV; Vozenin MC; Romero P
Clin Cancer Res; 2021 Jul; 27(14):4054-4065. PubMed ID: 33903200
[TBL] [Abstract][Full Text] [Related]
39. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
